WHO ICTRP trial
A multicenter, open, prospective, single-arm clinical study of…
ChiCTR2100054121 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100054121 |
|---|---|
| Public title | A multicenter, open, prospective, single-arm clinical study of ixazomib/pomalidomide/dexamethasone (IxaPD) in the treatment of patients with first relapsed multiple myeloma |
| Scientific title | A multicenter, open, prospective, single-arm clinical study of ixazomib/pomalidomide/dexamethasone (IxaPD) in the treatment of patients with first relapsed multiple myeloma |
| Primary sponsor | Henan Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Multiple myeloma |
| Interventions | therapy group:Ixazomib 4 mg orally; pomalidomide 4 mg orally; dexamethasone 40 mg orally [for patients over 75 years old, the dose of dexamethasone is reduced to 20 mg, and the cycle remains unchanged; 28 days is a cycle. |
| Registration date | Dec 9, 2021 |
| Target size | therapy group:60 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: